Release Date: 2024-05-28

Radical Cystectomy for Non-Muscle Invasive Bladder Cancer

Alpaslan Yuksel (Author)

Release Date: 2024-05-28

Radical cystectomy, removing the bladder, is an option for high-risk non-muscle invasive bladder cancer (NMIBC) that resists BCG therapy or has features like high-grade tumors. While it offers better cancer control, this major surgery carries risks of urinary diversion, sexual dysfunction, and fatigue. Doctors and patients should carefully weigh the benefits and drawbacks of this [...]

Media Type

  • PDF

Buy from

Price may vary by retailers

Work TypeBook Chapter
Published inCurrent Management of Non-Muscle Invasive Bladder Cancer
First Page169
Last Page177
DOIhttps://doi.org/10.69860/nobel.9786053359197.14
ISBN978-605-335-919-7 (PDF)
LanguageENG
Page Count9
Copyright HolderNobel Tıp Kitabevleri
Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

Radical cystectomy, removing the bladder, is an option for high-risk non-muscle invasive bladder cancer (NMIBC) that resists BCG therapy or has features like high-grade tumors. While it offers better cancer control, this major surgery carries risks of urinary diversion, sexual dysfunction, and fatigue. Doctors and patients should carefully weigh the benefits and drawbacks of this treatment for high-risk NMIBC.

Alpaslan Yuksel (Author)
Istanbul Medeniyet University
https://orcid.org/0000-0003-0076-4812
3Alpaslan Yuksel graduated from Marmara University Faculty of Medicine. He contributed to many academic publications and served as a faculty member for approximately 9 years. He made academic contributions to academic publications and abstracts of congress regarding Bladder Tumor.

  • Stewart BW, Bray F, Forman D, Ohgaki H, Straif K, Ullrich A, et al. Cancer prevention as part of precision medicine: ‘plenty to be done’. Carcinogenesis. 2016 Jan;37(1):2-9.

  • Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49.

  • Smith AB, Deal AM, Woods ME, Wallen EM, Pruthi RS, Chen RC, et al. Muscle-invasive bladder cancer: evaluating treatment and survival in the National Cancer Data Base. BJU Int. 2014 Nov;114(5):719-26.

  • Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013 Feb;63(2):234-41.

  • Sylvester RJ, Rodríguez O, Hernández V, Turturica D, Bauerová L, Bruins HM.et al. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. Eur Urol. 2021 Apr;79(4):480-488.

  • Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) 2019 Update. Eur Urol. 2019 Nov;76(5):639-657.

  • Jäger W, Thomas C, Haag S, Hampel C, Salzer A, Thüroff JW et al. Early vs delayed radical cystectomy for ‘high-risk’ carcinoma not invading bladder muscle: delay of cystectomy reduces cancer-specific survival. BJU Int. 2011 Oct;108(8 Pt 2):E284-8.

  • De Berardinis E, Busetto GM, Antonini G, Giovannone R, Gentile V. T1G3 highrisk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy. Int Urol Nephrol. 2011 Dec;43(4):1047-57.

  • Hautmann R.E., Volkmer B.G., Gust K. Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3) World J. Urol. 2009;27:347–351

  • Denzinger S, Fritsche HM, Otto W, Blana A, Wieland WF, Burger M. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol. 2008 Jan;53(1):146-52.

  • Catto JWF, Gordon K, Collinson M, Poad H, Twiddy M, Johnson M, et al. BRAVO study group. Radical Cystectomy Against Intravesical BCG for High-Risk HighGrade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study. J Clin Oncol. 2021 Jan 20;39(3):202-214.

  • Holzbeierlein JM, Bixler BR, Buckley DI, Chang SS, Holmes R, James AC, et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment. J Urol. 2024 Apr;211(4):533-538.

  • Gontero P, Birtle A, Compérat E, Dominguez Escrig J.L, Ledberg F, Mariiappan P, et. al. EAU Guidelines on Non-Muscle-Invasive Bladder Cancer (TaT1 and CIS) EAU Guidelines; Arnhem, The Netherlands: 2024.

  • Sylvester RJ, Rodríguez O, Hernández V, Turturica D, Bauerová L, Bruins HM et al. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. Eur Urol. 2021 Apr;79(4):480-488.

  • May M, Bastian PJ, Brookman-May S, Burger M, Bolenz C, Trojan L, et al. Pathological upstaging detected in radical cystectomy procedures is associated with a significantly worse tumor-specific survival rate for patients with clinical T1 urothelial carcinoma of the urinary bladder. Scand J Urol Nephrol. 2011 Sep;45(4):251-7.

  • Flitcroft M, Kothari A, Shah N, Knoll K, Johnson S. PD29-10 Facility level variatıon in pathologic upstaging of bladder cancer after radical cystectomy. J Urol 2023 Apr 1;209(Supplement 4):e828.

  • Moschini M, Sharma V, Dell’oglio P, Cucchiara V, Gandaglia G, Cantiello F, et al. Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy. BJU Int. 2016 Apr;117(4):604-10.

  • Schrier BP, Hollander MP, van Rhijn BW, Kiemeney LA, Witjes JA. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumors and implications for therapy. Eur Urol. 2004 Mar;45(3):292-6..

  • Kamat AM, Gee JR, Dinney CP, Grossman HB, Swanson DA, Millikan RE, et al. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol. 2006 Mar;175(3 Pt 1):881-5.

  • Gofrit ON, Yutkin V, Shapiro A, Pizov G, Zorn KC, Hidas G, et al. The Response of Variant Histology Bladder Cancer to Intravesical Immunotherapy Compared to Conventional Cancer. Front Oncol. 2016 Mar 15;6:43.

  • Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW, Amin MB. Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers. Eur Urol. 2018 Apr;73(4):560-569.

  • Mata DA, Groshen S, Von Rundstedt FC, Skinner DG, Stadler WM, Cote RJ, et al. Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder. J Surg Oncol. 2015 Jun;111(7):923-8.

  • Stein JP, Penson DF. Invasive T1 bladder cancer: indications and rationale for radical cystectomy. BJU Int 2008; 102:270.

  • Katsimperis S, Tzelves L, Tandogdu Z, Ta A, Geraghty R, Bellos T, et al. Complications After Radical Cystectomy: A Systematic Review and Meta-analysis of Randomized Controlled Trials with a Meta-regression Analysis. Eur Urol Focus. 2023 Nov;9(6):920-929.

  • Djaladat H, Katebian B, Bazargani ST, Miranda G, Cai J, Schuckman AK, et al. 90Day complication rate in patients undergoing radical cystectomy with enhanced recovery protocol: a prospective cohort study. World J Urol. 2017 Jun;35(6):907911.

  • Dybowski B, Ossoliński K, Ossolińska A, Peller M, Bres-Niewada E, Radziszewski P. Impact of stage and comorbidities on five-year survival after radical cystectomy in Poland: single centre experience. Cent European J Urol. 2015;68(3):278-83.

  • Ploussard G, Shariat SF, Dragomir A, Kluth LA, Xylinas E, Masson-Lecomte A, et al. Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time. Eur Urol. 2014 Aug;66(2):361-70

  • Crettenand F, M’Baya O, Grilo N, Valerio M, Dartiguenave F, Cerantola Y, et al. ERAS® protocol improves survival after radical cystectomy: A single-center cohort study. Medicine (Baltimore). 2022 Sep 2;101(35):e30258.

  • Chen W, Liu N, Yuan Y, Zhu M, Hu X, Hu W, Wang S, et al. ALT-803 in the treatment of non-muscle-invasive bladder cancer: Preclinical and clinical evidence and translational potential. Front Immunol. 2022 Nov 10;13:1040669.

  • Chamie K, Chang SS, Gonzalgo M, Kramolowsky EV, Sexton W.J, Bhar P et al. Final clinical results of the pivotal study of the IL-15RαFc superagonist N-803 with BCG in BCG-refractory CIS and papillary muscle non-invasive bladder cancer (NMIBC). J. Clin. Oncol. 2022 , 40: 4508.

  • Holzbeierlein JM, Bixler BR, Buckley DI, Chang SS, Holmes R, James AC, et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment. J Urol. 2024 Apr;211(4):533-538.

  • National Comprehensive Cancer Network. Bladder Cancer (Version 4.2024). https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf

onix_3.0::thothThoth ONIX 3.0
onix_3.0::project_museProject MUSE ONIX 3.0
onix_3.0::oapenOAPEN ONIX 3.0
onix_3.0::jstorJSTOR ONIX 3.0
onix_3.0::google_booksGoogle Books ONIX 3.0
onix_3.0::overdriveOverDrive ONIX 3.0
onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
csv::thothThoth CSV
json::thothThoth JSON
kbart::oclcOCLC KBART
bibtex::thothThoth BibTeX
doideposit::crossrefCrossRef DOI deposit
onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
marc21record::thothThoth MARC 21 Record
marc21markup::thothThoth MARC 21 Markup
marc21xml::thothThoth MARC 21 XML

Share This Chapter!